In Brief This Week: Agendia

US Oncology has joined its FLEX breast cancer registry study. The study is a large-scale, prospective, observational cancer study that links full genome profiling with clinical data to create a patient database that could be used to identify new gene associations with prognostic and/or predictive value in breast cancer. All US Oncology Research-affiliated sites can participate in FLEX with eight initial sites in Texas and Arizona open for enrollment.

Source: https://www.genomeweb.com/business-news/brief-week-molecularmd-agendia-promega-nrgene-more?utm_source=Sailthru&utm_medium=email&utm_campaign=Scan%20Fri%202018-09-14&utm_term=The%20Scan%20Bulletin